BYSI
BeyondSpring Inc.·Healthcare
1.74
1.695%(−0.03)
Market ClosedLast Updated: — ET
52W L: $1.1052W H: $3.44
BYSI NEWS
defenseworld.net
6d ago
BeyondSpring (NASDAQ:BYSI) Stock Passes Above 50 Day Moving Average – Here’s Why
BeyondSpring Inc. (NASDAQ: BYSI - Get Free Report) passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $1.52 and traded as high as $1.73. BeyondSpring shares last traded at $1.71, with a volume of 2,351 shares. Wall Street Analysts Forecast Growth Separately, Weiss Ratings
globenewswire.com
Mar 25
BeyondSpring Files 2025 Annual Report on Form 10-K
FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (“SEC”) on March 25, 2026. The annual report on Form 10-K, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at www.sec.gov and on the Company's website at www.beyondspringpharma.com under “Latest Results” in the Investors section. The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations, BeyondSpring Inc., 100 Campus Drive, Suite 410, Florham Park, NJ 07932 USA.
globenewswire.com
Feb 9
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the Company will participate in the Immuno-Oncology 360° (IO360°) Conference 2026, held February 10-12, 2026 in Boston, MA.
defenseworld.net
Jan 16
Financial Contrast: Lisata Therapeutics (NASDAQ:LSTA) vs. BeyondSpring (NASDAQ:BYSI)
BeyondSpring (NASDAQ: BYSI - Get Free Report) and Lisata Therapeutics (NASDAQ: LSTA - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk. Risk and Volatility BeyondSpring has a beta of
